Developing CAR-T Therapy for Treating B Cell Malignancies

Clara Wang, Haoyang Guo, Hanqin Yang, Beibo Kang

2022

Abstract

B cell lymphoma is a type hematopoietic malignancy with an average incidence rate of 4.3%. While B cell lymphoma is not as deadly as other solid tumors, aggressive lymphomas such as the diffuse large B cell lymphoma (DLBCL) can be fatal due to its fast-spreading characteristic and high metastatic ability. To more effectively target B-cell lymphomas, scientists have recently created the chimeric antigen receptor (CAR) that can actively detect the CD19 antigens secreted by cancer cells and directly activate T cells without binding to the major histocompatibility complex (MHC). However, over time, many cancer cells have also developed several mechanisms to escape the detection of T cells and to inhibit their function, which can significantly hamper the overall efficacy of traditional CAR-T therapy. Furthermore, traditional CAR-T therapies may also cause severe side effects, such as the cytokine release syndrome (CRS) caused by an overproduction of proinflammatory cytokines. In this study, we examined six current research articles that address these immune escape mechanisms as well as the side effects caused by traditional CAR-T therapies. We propose an experimental CAR-T therapy that combines the major findings from this primary research, which, if proven feasible, can substantially improve the overall efficacy of CAR cancer immunotherapy while significantly reducing damage caused by side effects.

Paper Citation

in Harvard Style

Wang C., Guo H., Yang H. and Kang B. (2022). Developing CAR-T Therapy for Treating B Cell Malignancies. In Proceedings of the 4th International Conference on Biotechnology and Biomedicine - Volume 1: ICBB; ISBN 978-989-758-637-8, SciTePress, pages 149-155. DOI: 10.5220/0012015100003633

in Bibtex Style

@conference{icbb22,
author={Clara Wang and Haoyang Guo and Hanqin Yang and Beibo Kang},
title={Developing CAR-T Therapy for Treating B Cell Malignancies},
booktitle={Proceedings of the 4th International Conference on Biotechnology and Biomedicine - Volume 1: ICBB},
year={2022},
pages={149-155},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0012015100003633},
isbn={978-989-758-637-8},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 4th International Conference on Biotechnology and Biomedicine - Volume 1: ICBB
TI - Developing CAR-T Therapy for Treating B Cell Malignancies
SN - 978-989-758-637-8
AU - Wang C.
AU - Guo H.
AU - Yang H.
AU - Kang B.
PY - 2022
SP - 149
EP - 155
DO - 10.5220/0012015100003633
PB - SciTePress